{"id":"98c4c8aa3ad4","type":"article","url":"https://hartvaat.nl/2026/11/07/standaard-osa-screening-tools-presteren-slecht-bij-hypertrofische-cardiomyopathi/","title":"Standaard OSA-screening tools presteren slecht bij hypertrofische cardiomyopathie","title_en":"Comparative validation of standard screening tools and an exploratory model for detecting obstructive sleep apnea in hypertrophic cardiomyopathy.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Sleep & breathing = Schlaf & Atmung","doi":"10.1007/s11325-026-03844-3","source_url":"https://doi.org/10.1007/s11325-026-03844-3","authors":["Shahid Karim","Balambika S Iyyappan","Sair Tabraiz","Aishwarya Rajendran","Anwar Chahal","Jeffrey B Geske","Alanna M Chamberlain","Virend K Somers"],"significance":4,"published":"2026-11-16","source_date":"2026-11-07","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"In a prospective cohort of 159 patients with hypertrophic cardiomyopathy (HCM), obstructive sleep apnea (OSA) was highly prevalent (57%), yet standard screening tools (STOP-Bang, ESS, Berlin) demonstrated poor diagnostic accuracy (AUC 0.58–0.62). An exploratory model using age, BMI, and waist-hip ratio showed improved performance (AUC 0.82), though it requires external validation. Cardiologists should be aware that conventional OSA screening instruments are unreliable in HCM, highlighting the need for disease-specific risk stratification to optimize referral for polysomnography.","created":"2026-11-09T02:45:42Z","updated":"2026-11-09T02:45:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In een prospectieve cohortstudie onder 159 patiënten met hypertrofische cardiomyopathie (HCM) bleek obstructieve slaapapneu (OSA) frequent voor te komen (57%), maar standaard screeningsvragenlijsten (STOP-Bang, ESS, Berlin) vertoonden een matige diagnostische nauwkeurigheid (AUC 0,58–0,62). Een verkennend model op basis van leeftijd, BMI en taille-heupverhouding scoorde beter (AUC 0,82), maar vereist nog externe validatie. Voor cardiologen betekent dit dat bestaande OSA-screeningtools niet betrouwbaar zijn in deze populatie, waardoor een op HCM toegespitste risicostratificatie nodig is om patiënten tijdig naar polysomnografie te verwijzen.","abstract_original":"STUDY OBJECTIVES: Despite representing a highly prevalent comorbidity, standard screening tools for obstructive sleep apnea (OSA) lack validation in the hypertrophic cardiomyopathy (HCM) population. We sought to prospectively evaluate the diagnostic accuracy of three widely used screening tools against gold-standard polysomnography in an HCM cohort and to explore the potential for a tailored predictive model. METHODS: In this prospective cohort study, patients with HCM completed the Epworth Sleepiness Scale (ESS), Berlin (BQ) and STOP-Bang questionnaires before undergoing inpatient overnight polysomnography. RESULTS: Of 159 participants (median age 60; 64% male), 90 (57%) had OSA (46% mild, 26% moderate, 28% severe). Standard tools yielded modest performance: STOP-Bang [AUC 0.59 (0.50-0.68), sensitivity 77% (68-86), specificity 40% (28-52)]; ESS [AUC 0.58 (0.49-0.67), sensitivity 24% (15-33), specificity 92% (86-98)]; and Berlin [AUC 0.62 (0.53-0.71), sensitivity 65% (55-75), specificity 57% (45-69)]. In contrast, an exploratory model incorporating age, BMI, and waist-hip ratio showed promising preliminary results [AUC 0.82 (0.74-0.88), sensitivity 60% (48-72), specificity 84% (75-91)]. CONCLUSIONS: This study underscores the high prevalence of OSA in patients with HCM and demonstrates that standard screening tools developed for the general population perform poorly in this cohort, complicating clinical triage when polysomnography is delayed. While the derived exploratory model may represent an improvement in risk stratification, these findings require extensive external validation. Targeted screening strategies tailored to the unique pathophysiology of HCM remain necessary to improve OSA identification and management in this high-risk population."}